OSTX

In the past six months, OS Therapies, Inc. (OSTX) stock was impacted by several events: in October 2026, the company announced a statistically significant final three-year overall survival benefit for Herlystic™ in its Phase 2b pulmonary metastatic osteosarcoma trial, which led to a stock price increase. Also in October 2026, Kerry Clem was appointed Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer. In September 2026, the World Health Organization (WHO) approved 'Herlystic' as the brand name for OST-HER2, and the company reported alignment with the FDA and accepted a Project Orbis invitation from the MHRA for its OST-HER2 program. In August 2026, OSTX shares declined by 9.3% following an earnings announcement, while in April 2026, the stock saw its largest daily move in the past year, increasing by 22.1%. Throughout this period, the company has been preparing and submitting for U.S. accelerated approval and U.K., European, and Australian conditional marketing authorization for Herlystic™. Over the last six months, the stock has increased by 19.12%, though it experienced a 17.35% fall in the last month and a 20.98% decrease over the last year.